AstraZeneca Pharma India Ltd
ASTRAZEN
Company Profile
Business description
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines.
Contact
Outer Ring Road
Block N1, 12th Floor
Manyata Embassy Business Park
Rachenahalli
BangaloreKA560 045
INDT: +91 8067748000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
940
Stocks News & Analysis
stocks
The ASX healthcare player soaring to all-time highs
The steep market reaction comes after a recent announcement by the ACCC
stocks
Ask the analyst: How long is WiseTech's growth runway?
Roy Van Keulen answers my question on how big a growth opportunity remains for the ASX's biggest technology company.
video
Why the ASX's most overlooked world champion is no dinosaur
Brambles is the undisputed king of pallet pooling. Esther Holloway joined me to talk about its moat, growth prospects and risk of disruption.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,416.60 | 57.70 | -0.68% |
| CAC 40 | 7,541.36 | 63.58 | 0.85% |
| DAX 40 | 19,120.93 | 105.52 | 0.55% |
| Dow JONES (US) | 42,352.75 | 341.16 | 0.81% |
| FTSE 100 | 8,280.63 | 1.89 | -0.02% |
| HKSE | 22,736.87 | 623.36 | 2.82% |
| NASDAQ | 18,137.85 | 219.37 | 1.22% |
| Nikkei 225 | 38,635.62 | 83.56 | 0.22% |
| NZX 50 Index | 12,619.94 | 47.28 | 0.38% |
| S&P 500 | 5,751.07 | 51.13 | 0.90% |
| S&P/ASX 200 | 8,150.00 | 55.20 | -0.67% |
| SSE Composite Index | 3,336.50 | 248.97 | 8.06% |